J Retin.  2024 Nov;9(2):127-133. 10.21561/jor.2024.9.2.127.

Short-term Anatomical Outcomes of Switching from Bevacizumab to the Ranibizumab Biosimilar CKD-701 in Neovascular Age-related Macular Degeneration

• Yoon YS
• Kim JH

• KMID: 2561874
• DOI: http://doi.org/10.21561/jor.2024.9.2.127

Abstract

Purpose
To evaluate and report the short-term anatomical effects of switching from bevacizumab to the ranibizumab biosimilar CKD-701 in patients undergoing treatment for neovascular age-related macular degeneration (AMD).
Methods
A retrospective medical record analysis was conducted on patients receiving bevacizumab therapy for neovascular AMD who were subsequently switched to CKD-701. The changes in central macular thickness and frequency of intraretinal/subretinal fluid before and after a single CKD-701 injection were compared with those before and after a single bevacizumab injection.
Results
A total of 20 eyes was included in the study. Following bevacizumab injection, the mean central macular thickness decreased by 14.9 ± 57.6 µm, with intraretinal and subretinal fluid observed in 75.0%/55.0% before injection and 60.0%/55.5% after injection, respectively. Following CKD-701 injection, the mean central macular thickness decreased by 34.9 ± 57.4 µm, with intraretinal and subretinal fluid observed in 75.0%/56.0% before injection and 45.0%/40.0% after injection, respectively. There were no significant differences between the two groups in terms of changes in central macular thickness (p = 0.204), frequency of intraretinal fluid (p = 1.000), and subretinal fluid (p = 0.748) observed before injection or in frequency of intraretinal fluid (p = 0.527) and subretinal fluid (p = 0.527) after injection.
Conclusions
The short-term anatomical outcomes following CKD-701 injection in neovascular age-related macular degeneration showed no significant difference compared to the short-term outcomes following bevacizumab injection previously administered.

Keyword

Age-related macular degeneration; Bevacizumab; Biosimilar; Choroidal neovascularization; CKD-701